Patricia R. Mayer-Brennan, PhD
Dr. Mayer-Brennan oversees IPM’s efforts to obtain regulatory approval for IPM’s products and collaborates with global regulatory authorities to ensure compliance with the drug development regulations and guidelines.
With more than 17 years’ experience managing and developing regulatory strategies for pharmaceutical companies in the US and Europe, Dr. Mayer-Brennan has worked with regulatory authorities around the world. Most recently, she served as vice president of regulatory affairs at Perosphere Inc., where she oversaw regulatory strategies for drug and device development and established fully compliant regulatory operations. She previously held senior leadership positions managing regulatory portfolios for therapeutic products at MannKind Corporation and Purdue Pharma L.P. and for diagnostic imaging agents at Berlex Laboratories, Inc. and Schering AG, Germany. Dr. Mayer-Brennan has also worked as an independent regulatory strategy consultant.
Dr. Mayer-Brennan holds an MSc in animal physiology and a PhD in biology from the University of Tuebingen in Germany.